231 related articles for article (PubMed ID: 29262697)
1. Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.
Durand C; Bylo M; Howard B; Belliveau P
Ann Pharmacother; 2018 Jun; 52(6):580-590. PubMed ID: 29262697
[TBL] [Abstract][Full Text] [Related]
2. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.
Hong J; Krop LC; Johns T; Pai MP
Pharmacotherapy; 2015 May; 35(5):455-63. PubMed ID: 26011138
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.
Masich AM; Kalaria SN; Gonzales JP; Heil EL; Tata AL; Claeys KC; Patel D; Gopalakrishnan M
Pharmacotherapy; 2020 Mar; 40(3):211-220. PubMed ID: 31957057
[TBL] [Abstract][Full Text] [Related]
4. Performance of a divided-load intravenous vancomycin dosing strategy for obese patients.
Denetclaw TH; Yu MK; Moua M; Dowling TC; Steinke D
Ann Pharmacother; 2015 Aug; 49(8):861-8. PubMed ID: 25986008
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
6. The association of elevated trough serum vancomycin concentrations with obesity.
Richardson J; Scheetz M; O'Donnell EP
J Infect Chemother; 2015 Jul; 21(7):507-11. PubMed ID: 25851852
[TBL] [Abstract][Full Text] [Related]
7. Dosing vancomycin in the super obese: less is more.
Crass RL; Dunn R; Hong J; Krop LC; Pai MP
J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.
Medellín-Garibay SE; Ortiz-Martín B; Rueda-Naharro A; García B; Romano-Moreno S; Barcia E
J Antimicrob Chemother; 2016 Feb; 71(2):471-9. PubMed ID: 26568565
[TBL] [Abstract][Full Text] [Related]
10. Concordance of Vancomycin Population-Predicted Pharmacokinetics with Patient-Specific Pharmacokinetics in Adult Hospitalized Patients: A Case Series.
Onor IO; Neuliep A; Tran KA; Lambert J; Gillard CJ; Brakta F; Ezebuenyi MC; St James K; Okogbaa JI; Beyl RA
Drugs R D; 2020 Jun; 20(2):83-93. PubMed ID: 32166646
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
12. Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations.
Brown ML; Hutchison AM; McAtee AM; Gaillard PR; Childress DT
Am J Health Syst Pharm; 2017 Jul; 74(14):1067-1075. PubMed ID: 28522643
[TBL] [Abstract][Full Text] [Related]
13. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
[TBL] [Abstract][Full Text] [Related]
14. Performance of a vancomycin dosage regimen developed for obese patients.
Reynolds DC; Waite LH; Alexander DP; DeRyke CA
Am J Health Syst Pharm; 2012 Jun; 69(11):944-50. PubMed ID: 22610026
[TBL] [Abstract][Full Text] [Related]
15. Review and evaluation of vancomycin dosing guidelines for obese individuals.
Wong S; Reuter SE; Jones GR; Stocker SL
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):323-335. PubMed ID: 35815356
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin trough concentrations in overweight or obese pediatric patients.
Heble DE; McPherson C; Nelson MP; Hunstad DA
Pharmacotherapy; 2013 Dec; 33(12):1273-7. PubMed ID: 23798327
[TBL] [Abstract][Full Text] [Related]
17. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.
Frazee E; Rule AD; Lieske JC; Kashani KB; Barreto JN; Virk A; Kuper PJ; Dierkhising RA; Leung N
Am J Kidney Dis; 2017 May; 69(5):658-666. PubMed ID: 28131530
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population.
Turner RB; Kojiro K; Won R; Chang E; Chan D; Elbarbry F
Diagn Microbiol Infect Dis; 2018 Dec; 92(4):346-351. PubMed ID: 30025969
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients.
Eiland LS; Sonawane KB
J Pediatr Pharmacol Ther; 2014 Jul; 19(3):182-8. PubMed ID: 25309148
[TBL] [Abstract][Full Text] [Related]
20. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
